0.00Open0.00Pre Close0 Volume0 Open Interest35.00Strike Price0.00Turnover598.97%IV-1036.36%PremiumJan 17, 2025Expiry Date31.92Intrinsic Value100Multiplier23DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8121Delta0.0632Gamma0.10Leverage Ratio-0.0247Theta-0.0108Rho-0.08Eff Leverage0.0021Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet